Compare Church & Dwight Co., Inc. (CHD) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Davita Inc — how do they compare? Church & Dwight Co., Inc. trades at $97.03 (market cap $23.02B), while Davita Inc trades at $232 (market cap $15.12B). The key difference: Church & Dwight Co., Inc. is the larger of the two by market cap, and Church & Dwight Co., Inc. pays a 1.27% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| CHD | DVA | |
|---|---|---|
Market Cap | $23.02B | $15.12B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $235.71 |
52-Week Low | $81.60 | $103.87 |
Enterprise Value | $24.72B | $27.67B |
Dividend Yield | 1.27% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
